In this downloadable slideset, Val R. Adams, PharmD, FCCP, BCOP, reviews the landscape of EGFR mutations in advanced NSCLC and the pharmacology of EGFR tyrosine kinase inhibitors used in this setting.
In this downloadable slideset, H. Jack West, MD, reviews the latest first-line and second-line clinical data in the setting of EGFR mutation–positive NSCLC.
In this downloadable slideset, Philip Schwieterman, PharmD, MHA, reviews pharmacy perspectives in the delivery of care to patients with EGFR-mutated NSCLC.
In this on-demand CPE-certified Webcast of a CCO symposium at HOPA 2018, Val R. Adams, PharmD, FCCP, BCOP; Philip Schwieterman, PharmD, MHA; and H. Jack West, MD, review and discuss the latest data on EGFR-targeted therapies for advanced EGFR-mutated NSCLC as they apply to pharmacists.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.